Associations of fibroblast growth factor 23 and fetuin-A with coronary plaque burden and plaque composition in young adults

Journal of Investigative Medicine

Volumn 63, Issue 4, 2015, Pages 613-619

  Akin, Fatih ^a   Celik, Omer ^b   Ayca, Burak ^c   Altun, Ibrahim ^a   Diker, Vesile Ornek ^b   Byk, Ismail ^b   Siriopol, Dimitrie ^d   Covic, Adrian ^d   Kanbay, Mehmet ^e  

^a Department of Cardiology Mu la Stk Kocman University School of Medicine   (Turkey)

^b Istanbul Mehmet Akif Ersoy Cardiovascular Surgery Education and Research Hospital   (Turkey)

^c Baʇclar Education and Research Hospital ^*  (Turkey)

^d GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e KOÇ UNIVERSITY   (Turkey)

Author keywords

coronary computed tomography angiography; fetuin A; fibroblast growth factor 23; subclinical atherosclerosis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; FETUIN A; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URIC ACID; AHSG PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR;

ADULT; AGE DISTRIBUTION; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; YOUNG ADULT; BLOOD; FEMALE; MALE; METABOLISM; PLAQUE, ATHEROSCLEROTIC; RISK FACTOR;

ADULT; ALPHA-2-HS-GLYCOPROTEIN; BIOMARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS;

EID: 84926156277     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1097/JIM.0000000000000153     Document Type: Article

References (37)

1. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429-435.
2. Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-592.
3. Nasrallah MM, El-Shehaby AR, Salem MM, et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25: 2679-2685.
4. Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2009;24:948-955.
5. Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119:2545-2552.
6. BalciM,Kirkpantur A,GulbayM, et al. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int. 2010;14:425e32.
7. MirzaMA, Larsson A, Lind L, et al. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205:385-390.
8. Kanbay M, Nicoleta M, Selcoki Y, et al. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5:1780e6.
9. Masai H, Joki N, Sugi K, et al. A preliminary study of the potential role of FGF-23 in coronary calcification in patientswith suspected coronary artery disease. Atherosclerosis. 2013;226:228-233.
10. Lebreton JP, Joisel F, Raoult JP, et al. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest. 1979;64:1118-1129.
11. Cozzolino M, Galassi A, Biondi ML, et al. Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. Am J Nephrol. 2006;26:423-429.
12. Mori K, Ikari Y, Jono S, et al. Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis. 2010;21:281-285.
13. RittigK, Thamer C,Haupt A, et al. High plasma fetuin-A is associatedwith increased carotid intima-media thickness in a middle-aged population. Atherosclerosis. 2009;207(2):341-342.
14. Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361:827-833.
15. Ix JH, Biggs ML, Mukamal KJ, et al. Association of fetuin-a with incident diabetes mellitus in community-living older adults: the cardiovascular health study. Circulation. 2012;125(19):2316-2322.
16. Laughlin GA, Cummins KM,Wassel CL, et al. The association of fetuin-A with cardiovascular disease mortality in older community-dwelling adults: the Rancho Bernardo study. J Am Coll Cardiol. 2012;59:1688-1696.
17. Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975;51:5-40.
18. Leber AW, Becker A, Knez A, et al. Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol. 2006;47:672-677.
19. Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? J Am Soc Nephrol. 1999;10:2426-2439.
20. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001;103:2705-2710.
21. Chen YC, Lin FY, Lin RH, et al. Relation between fetuin-A levels and fibroblast growth factor 23 with the severity of coronary artery disease measured by SYNTAX scores. Am J Cardiol. 2013;112:950-953.
22. Donate-Correa J, Mora-Fernández C,Martínez-Sanz R, et al. Expression of FGF23/KLOTHO system in human vascular tissue. Int J Cardiol. 2013; 165:179-183.
23. Lim K, Lu TS, Molostvov G, et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to FGF-23. Circulation. 2012;125:2243-2255.
24. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205-2215.
25. Tuñón J, Cristóbal C, Tarín N, et al. Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. PLoS One. 2014;9:e95402.
26. Pertosa G, Simone S, Ciccone M, et al. Serum fetuin a in hemodialysis: a link between derangement of calcium-phosphorus homeostasis and progression of atherosclerosis? Am J Kidney Dis. 2009;53: 467-474.
27. Akyuz A, Oran M, Alpsoy S, et al. Association between serum fetuin-A levels, carotid artery stiffness, and intima-media thickness in patients with normotensive obstructive sleep apnea syndrome. Angiology. 2013;65: 607-613.
28. Dogru T, Genc H, Tapan S, et al. Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf ). 2013;78:712-717.
29. Fiore CE, Celotta G, Politi GG, et al. Association of high alpha2-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patientswith atherosclerotic vascular disease and low bone mass. Atherosclerosis. 2007;195:110-115.
30. Weikert C, Stefan N, Schulze MB, et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008;118: 2555-2562.
31. Mehrotra R, Westenfeld R, Christenson P, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 2005;67:1070-1077.
32. Auberger P, Falquerho L, Contreres JO, et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell. 1989;58:631-640.
33. Srinivas PR, Wagner AS, Reddy LV, et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol. 1993;7:1445-1455.
34. Xu Y, Xu M, Bi Y, et al. Serum fetuin-A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis. 2011;216: 180-186.
35. Coen G, De Paolis P, Ballanti P, et al. Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23. J Nephrol. 2011;24:313-321.
36. Roos M, Lutz J, Salmhofer H, et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf ). 2008;68:660-665.
37. Voigt M, Fischer DC, Rimpau M, et al. Fibroblast growth factor (FGF)-23 and fetuin-A in calcified carotid atheroma. Histopathology. 2010;56(6): 775-788.